ImmuneRegen BioSciences® Adds Renowned Scientists to Advisory Board
ImmuneRegen BioSciences®, a wholly owned subsidiary of IR Biosciences Holdings Inc.(OTC BB:IRBS.OB), today announced that Adriana T. Larregina, M.D., Ph.D., and Jacob Finkelstein, Ph.D. have accepted invitations to join...
Adriana T. Larregina, M.D., Ph.D., and Jacob Finkelstein, Ph.D. to Collaborate with Company to Advance Commercialization of Adult Stem Cell-Active Compound, Homspera®
SCOTTSDALE, AZ -- (April 14, 2009) -- ImmuneRegen BioSciences®
Dr. Larregina, a University of Pittsburgh School of Medicine faculty member of the Dermatology and Immunology departments and director of the school’s Cutaneous Biology Laboratories and Education, has published extensively on the role dendritic cells and their precursors play in stimulating immune responses. Further, she has utilized the active component of ImmuneRegen’
Dr. Finkelstein, a professor in the departments of Pediatrics, Radiation Oncology and Environmental Medicine at the University of Rochester Medical School, is recognized for his investigations into the effects of radiation on cells and functions of the lung. Dr. Finkelstein’
“The intellectual contributions of these two talented scientists to our advisory board are immeasurable,”
ImmuneRegen is developing Homspera, a neurokinin-1 receptor-specific analog of Substance P, as a potential adjuvant for incorporation into vaccines or for therapeutic applications. Initial studies by ImmuneRegen have confirmed adjuvant activity for Homspera with a number of antigens and as a protective agent following exposure to high doses of radiation.
Over the past 15 years, Dr. Larregina has pioneered studies exploring the role of dendritic cells in the human immune system and has published numerous peer-reviewed manuscripts, invited reviews and book chapters in this field. She spent the early part of her career studying and practicing pathology in her native Buenos Aires, Argentina, prior to moving to the United States in 1998.
Her industry-related memberships include the Society for Investigative Dermatology and the American Association of Immunologists.
Dr. Larregina holds an M.D. from the National University of La Plata School of Medicine in Buenos Aires, and a Ph.D. in Immunology from the University of Buenos Aires School of Medicine.
Dr. Finkelstein, a project leader at the University’s Center for Biophysical Assessment and Risk Management Following Irradiation (CBARMFI), has presented his research at numerous international conferences and has been published in peer-reviewed journals, textbooks and technical reports. He has served as a grant-reviewer for a number of prominent associations, including the National Institutes of Health (National Institute of Allergy and Infectious Diseases), American Lung Association and the Veteran’s Administration, and serves on the editorial boards of many scientific journals.
His industry-related memberships include the American Association for the Advancement of Science, the American Chemical Society (Division of Biological Chemistry) and the American Society for Biochemistry and Molecular Biology.
Dr. Finkelstein holds a Ph.D. in Biochemistry from Northwestern University and a bachelor’s degree in chemistry from Carnegie-Mellon University.
About ImmuneRegen BioSciences Inc.
ImmuneRegen BioSciences Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC BB:IRBS.OB - News), is a development-
Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-KSB for the year ended December 31, 2008 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements.
ImmuneRegen BioSciences Inc.
# # #